- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06372158
Effects of Liposomal Encapsulation on Calcium Powder Absorption and Metabolism
April 12, 2024 updated by: YenPing, Lei, National Yang Ming University
Compared with traditional calcium supplements, liposome calcium can increase the bioavailability of calcium and reduce the waste caused by gastric acid destruction of calcium.
This allows calcium to be released slowly in the intestines, reducing the risk of indigestion or other side effects caused by excessive intake at one time.
Liposomal calcium can be taken orally directly.
It does not need to be dissolved in water before taking like other calcium supplements, making it more convenient to use.
Based on the above advantages, liposomal calcium is a relatively safe and easy-to-absorb calcium supplement, suitable for long-term use, and can meet the body's demand for calcium.
According to the recommendations of the World Health Organization, the daily calcium intake for adults should be 1000-1300 mg.
In Taiwan, the seventh edition of the revised reference intake of dietary nutrients for Chinese people recommends that the daily intake for adults should be 1,000 mg.
The calcium dose used in this study was 500 mg.
The purpose was to explore whether the sustained-release characteristics of liposome coating technology can improve the absorption rate after consuming calcium powder and achieve better bioavailability.
It is expected that microlipids made by lecithin can Lipid calcium powder increases its maintenance time in the blood, thereby increasing the supplementary effect of calcium, and is an alternative to calcium supplements.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Taipei, Taiwan, 112
- Recruiting
- National Yang Ming Chiao Tung University
-
Contact:
- ChienYu Huang, Bachelor
- Phone Number: +886-955-879163
- Email: chienyu.ns11@nycu.edu.tw
-
-
Beitou Dist.
-
Taipei, Beitou Dist., Taiwan, 112
- Recruiting
- National Yang Ming Chiao Tung University
-
Contact:
- Tze-Fang Wang, Ph.D.
- Phone Number: +886-2-28267907
- Email: tzefang@nycu.edu.tw
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Adults aged 20-60 years old, without heart, liver, kidney, endocrine or major organic diseases (patient report), and able to fully cooperate with the experiment.
Exclusion Criteria:
- Patients with renal insufficiency and dialysis
- Cancer patients
- Underweight (BMI#17) or obese (BMI#27)
- Those taking medications for chronic diseases
- Blood pressure systolic blood pressure # 130 mmHg or diastolic blood pressure # 85 mmHg
- Fasting blood glucose # 100 mg/dL
- Fasting triglycerides # 150 mg/dL, total cholesterol # 200 mg/dL
- Have a history of vitamin C allergy
- People suffering from mental illness
- Pregnant and breastfeeding women
- Patients with hemosiderosis
- Kidney stone patients
- Supplements for those who take calcium for a long time
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Stage 1
Day 14
|
Number 1-10 :General vitamin C powder group (Contains 1500 mg Ca); Number 11-20: liposomal encapsulation Ca powder group (Contains 1500 mg of Ca and lecithin and is coated)
|
|
Other: Stage 2
Day 28
|
Number 11-20 :General vitamin C powder group (Contains 1500 mg Ca); Number 1-10: liposomal encapsulation Ca powder group (Contains 1500 mg of Ca and lecithin and is coated)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
General examination
Time Frame: Day 14 and 28
|
BMI(Body Mass Index is a simple calculation using a person's height and weight.
The formula is BMI = kg/m2 where kg is a person's weight in kilograms and m2 is their height in metres squared) and blood pressure
|
Day 14 and 28
|
|
Hematology Test
Time Frame: Day 14 and 28
|
Fasting blood glucose, triglycerides, total cholesterol, Blood urea nitrogen, Creatinine(Blood urea nitrogen (BUN) and creatinine tests can be used together to find the BUN-to-creatinine ratio (BUN:creatinine).
A BUN-to-creatinine ratio can help your doctor check for problems, such as dehydration, that may cause abnormal BUN and creatinine levels.),
GOT, GPT
|
Day 14 and 28
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
April 8, 2024
Primary Completion (Estimated)
December 1, 2024
Study Completion (Estimated)
December 1, 2024
Study Registration Dates
First Submitted
April 2, 2024
First Submitted That Met QC Criteria
April 12, 2024
First Posted (Actual)
April 17, 2024
Study Record Updates
Last Update Posted (Actual)
April 17, 2024
Last Update Submitted That Met QC Criteria
April 12, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NYCU112181AE
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoporosis
-
Radius Health, Inc.CompletedOsteoporosis | Osteoporosis Risk | Osteoporosis, Postmenopausal | Osteoporosis Fracture | Osteoporosis, Age-Related | Osteoporosis Localized to Spine | Osteoporosis Senile | Osteoporosis of Vertebrae | Osteoporosis VertebralUnited States
-
Radius Health, Inc.CompletedOsteoporosis | Age Related Osteoporosis | Osteoporosis, Age-Related | Osteoporosis Localized to Spine | Osteoporosis Senile | Osteoporosis of VertebraeUnited States, Poland, Italy
-
National Taiwan University HospitalRecruitingOsteoporosis | Osteoporosis PostmenopausalTaiwan
-
Appalachian State UniversityNorth Carolina Agriculture & Technical State UniversityCompletedPostmenopausal Osteoporosis | Osteoporosis, OsteopeniaUnited States
-
Hoffmann-La RocheCompletedPostmenopausal OsteoporosisUnited States
-
Hoffmann-La RocheCompletedPost Menopausal OsteoporosisUnited States, Puerto Rico
-
mAbxience Research S.L.CompletedPostmenopausal Women With OsteoporosisPoland, Serbia, Bulgaria, Georgia, Estonia, Hungary, Latvia, Mexico
-
Radius Health, Inc.Nordic Bioscience A/SCompletedPost Menopausal OsteoporosisPoland, Denmark, United States, Estonia
-
Centre Hospitalier Universitaire de Saint EtienneMinistry of Health, FranceRecruitingPost Menopausal OsteoporosisFrance
-
AmgenCompletedPost Menopausal OsteoporosisFrance
Clinical Trials on Stage 1
-
Merck Sharp & Dohme LLCRecruitingPneumococcal InfectionUnited States
-
Nantes University HospitalUniversité de Nantes; University of Paris 13; Institut de Recherche en Santé... and other collaboratorsCompleted
-
Fox Chase Cancer CenterUniversity of South Carolina; Temple University; Thomas Jefferson University; Rutgers...RecruitingCervical Cancer | Papilloma Viral InfectionUnited States
-
University of Nevada, RenoNational Institute of Mental Health (NIMH); The Catholic University of AmericaCompleted
-
University of MichiganNational Institute of Mental Health (NIMH)CompletedDepression | AnxietyUnited States
-
Heuron Inc.CompletedIschemic StrokeKorea, Republic of
-
Altheos, Inc.UnknownPrimary Open Angle Glaucoma | Ocular HypertensionUnited States
-
a2 Milk Company Ltd.Completed
-
University Hospital Schleswig-HolsteinHanse-Klinik, Fachklinik für Liposuktion, Lübeck; Praxisklinik Kronshagen,...Recruiting
-
Corporal Michael J. Crescenz VA Medical CenterVA Pittsburgh Healthcare SystemCompleted